Biotech

All Articles

Amgen documents very first phase 3 win for $400M dermatitis medication

.Amgen has shared (PDF) the very first period 3 information on its own $400 thousand chronic eczema ...

Biogen, UCB file period 3 lupus gain after stopping working earlier trial

.Biogen as well as UCB's rely on improving right into period 3 on the back of a broken study seeks t...

Aptadir wishes new RNA inhibitors can reverse difficult cancers

.Italian biotech Aptadir Therapeutics has actually launched along with the pledge that its own pipe ...

Wave surfs DMD effectiveness to regulatory authorities' doors, sending out stock up

.Surge Lifestyle Sciences has satisfied its goal in a Duchenne muscular dystrophy (DMD) research stu...

Sanofi picks brand new CSO coming from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is actually coming back to the pharma layer, usi...

Achilles drips cell treatment course, supports for discharges after overlooking 'commercial viability' targets

.Achilles Rehabs has actually shreded its own approach. The English biotech is stopping work on its ...

Aligos proclaims phase 2 MASH gain, reducing liver body fat approximately 46%

.Aligos Therapies is trumpeting a midstage succeed in metabolic-dysfunction linked steatohepatitis (...

Basilea credit ratings $268M BARDA financing for antifungals, anti-biotics

.Basilea Pharmaceutica's job building brand new antifungals has obtained a substantial boost from th...

Capricor sells Europe legal rights to late-stage DMD treatment for $35M

.Having currently gathered up the united state rights to Capricor Rehabs' late-stage Duchenne muscle...

FDA scraps adcomm for Applied's unusual health condition medication

.After pushing the selection meeting for Applied Rehabs' metabolic condition drug govorestat, the FD...